The agency that decides which drugs reach patients and what ends up on store shelves is back to square one on leadership. The White House has withdrawn the nomination of Heidi Overton to lead the FDA, and it did so a day before a pivotal Senate committee vote. Kyle Diamantas has been acting commissioner since May, and the withdrawal means the search for a permanent head starts over.
The name now circulating is Senator Roger Marshall of Kansas, who is being weighed as a replacement according to two sources. That is reporting about consideration, not a decision, and nothing in it confirms that an offer has been made or accepted. Kalshi traders put the chance that Marshall is nominated before the end of the year at 22% as of 8:21 a.m. ET on Nov. 19, down 19 points in the last day. That is a thin market, with 884 contracts traded over the last day and 693 contracts open, so the price reflects limited trading rather than a deep pool of opinion. A price that has fallen that far in a single day also says the question is far from settled in the minds of the people trading it.
The other names Kalshi lists for the job are not drawing any trading. Brett Giroir, Kyle Diamantas, Nicole Saphier and Sara Brenner each sit at 0% with no contracts traded, which means the market currently offers no read on them at all. In practice the contest is a single priced candidate and a long list of blanks. The market closes on Jan. 1, 2027, so it covers only whether a nomination comes before the year ends, not whether anyone is confirmed.
Why the pick fell apart matters for what comes next, and the reporting points to resistance from medical groups. Overton's nomination drew opposition over vaccine positions: Overton's support of that order unnerved several medical groups. A review of the abortion pill mifepristone is also underway, with results expected by March 2027, a reminder that the person who eventually leads the agency will inherit contested decisions as soon as they arrive. The political ground has shifted too. Several members of the Senate health committee lost their re-election bids, Marshall among them, which complicates any assumption about who holds leverage in the coming months.
For readers, the practical question is how much a leadership gap matters in daily terms. Acting service is limited to 210 days, and the withdrawal resets that clock, so the agency could run on an acting basis for months rather than weeks. One analyst view is that FDA operations are likely to continue running reasonably smoothly, which suggests the routine work of reviewing products and handling inspections is not expected to stall. Even so, an agency without a confirmed head has less standing to make the biggest calls, and the people most affected are patients waiting on decisions and companies waiting on answers.
What remains unsettled is considerable. It is not yet clear whether Marshall is truly the choice, whether the White House names anyone before the new year, or whether Diamantas stays on as acting leader in the meantime. For now, the only priced possibility is a single senator's name on a thin book, and the rest of the field is silence.



